MedTrace Logo

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

NCT00501332 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-12-24

No results posted yet for this study

Summary

This is an investigation of the safety and efficacy of Maxy-G34 in breast cancer patients treated with TAC chemotherapy. Maxy-G34 will be given as a single injection during each cycle of chemotherapy, for a planned total of six chemotherapy cycles.

Conditions

Interventions

BIOLOGICAL

Maxy-G34

Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.

Sponsors & Collaborators

  • Maxygen ApS

    collaborator INDUSTRY

  • Maxygen, Inc.

    collaborator INDUSTRY

  • Parexel

    collaborator INDUSTRY

  • Maxygen Holdings Ltd.

    lead INDUSTRY

Principal Investigators

  • Santosh Vetticaden, MD · Maxygen, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31

Countries

  • Poland
  • Romania
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501332 on ClinicalTrials.gov